Are there generic versions of capmatinib on the market?

Capmatinib trade nameTabrecta is a highly selective MET tyrosine kinase inhibitor used to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. The drug was developed by Novartis Pharmaceuticals and received accelerated approval from the US FDA in May 2020. It became the first targeted therapy drug for METex14 mutated lung cancer, marking a further subdivision and in-depth development of precision treatment of lung cancer. However, as an original and innovative drug, it is relatively expensive, posing great financial pressure on some patients around the world, especially self-paying patients. Therefore, whether generic drugs of capmatinib have entered the market has become a matter of great concern to patients.

At present, "generic drugs" of capmatinib have been put into use globally in some overseas regions, especially in the pharmaceutical market in Southeast Asia. These drugs are mostly produced by local pharmaceutical factories under relatively relaxed patent protection laws and have the same active ingredients and dosage specifications as the original drugs. For example, the generic capmatinib drug produced by Lucius Pharmaceuticals in Laos has a specification of 200 mg and 56 tablets per box, and the market price is about more than 3,000 yuan. This price is far lower than the market retail price of the original drug, which significantly eases the financial burden on patients. However, the specific selling price may be affected by external factors such as exchange rate changes and logistics costs.

From a pharmacological perspective, if generic drugs pass qualified bioequivalence verification, their clinical efficacy and safety should be basically the same as those of the original drugs. Some generic drug companies in Laos, Bangladesh and other countries have certain internationally certified production capabilities, and their products are also regarded as economic alternatives.

In short, the emergence of generic capmatinib drugs is a positive signal for the popularization of targeted tumor therapy. However, at this stage, price and safety should be weighed, and legal and quality-controllable drug sources should be selected to ensure treatment efficacy and drug safety.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib